LCM
BBIO icon

Landscape Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Landscape Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-22,554
Closed -$1.17M – 724
2025
Q3 		$1.17M Sell
22,554
-13,456
-37% -$656K 0.07% 336
2025
Q2 		$1.55M Buy
+36,010
New +$1.31M 0.12% 245
2019
Q3 		– Sell
-38,679
Closed -$1.04M – 650
2019
Q2 		$1.04M Buy
+38,679
New +$1.05M 0.08% 265

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Landscape Capital Management's BBIO Position: Q4 2025 in Review

Landscape Capital Management sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 22,554 shares — an estimated $1.17M sold.

Landscape Capital Management first reported a position in BBIO in Q2 2019 and held it in 3 quarters. The position peaked at $1.55M in Q2 2025. 433 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • Landscape Capital Management reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
  • Landscape Capital Management sold 22,554 BridgeBio Pharma shares in Q4 2025, an estimated $1.17M.
  • Landscape Capital Management first reported a position in BridgeBio Pharma in Q2 2019 and held it in 3 quarters.
  • Landscape Capital Management's BridgeBio Pharma position peaked at $1.55M in Q2 2025.
  • 433 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Landscape Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.